Introduction {#sec1_1}
============

Patients exhibiting one of the local signs of inflammation, such as Murphy\'s sign, a mass, pain, jaundice, or tenderness in the right upper quadrant, and systemic inflammation are diagnosed as having acute cholangitis or cholecystitis. Patients with clinical findings that are confirmed by diagnostic imaging are also diagnosed with acute cholangitis or cholecystitis. In these patients, a therapy with appropriate antimicrobial agents is an important component of the management. The goal of antimicrobial therapy in acute cholangitis and cholecystitis is to limit the systemic septic response and local inflammation \[[@B1]\].

Acute cholangitis and cholecystitis are common conditions that may result in progressively severe infection, particularly in debilitated hosts. An appropriate treatment is required in the acute phase. Severe acute cholangitis or cholecystitis may result in early death if appropriate medical care is not provided \[[@B2],[@B3],[@B4],[@B5],[@B6]\]. An attempt to develop a clinical guidance was provided by the Tokyo Guidelines (TG) 2007 in which international standards for diagnostics and severity assessment criteria for acute cholecystitis and cholangitis were defined for the first time \[[@B2]\].

Here, we discuss antimicrobial agents that are suitable for the first-line management of these infections. We focus primarily on empirical therapy (presumptive therapy), which is provided before the infecting isolates are identified. Such therapy depends upon the knowledge of local microbial epidemiology and patient-specific factors affecting the selection of appropriate agents \[[@B3]\].

Etiology and Pathogenesis {#sec1_2}
=========================

Acute biliary infections are systemic infectious diseases requiring prompt treatment. Acute cholangitis and cholecystitis are conditions with acute inflammation and infection of the biliary system, which are often accompanied by chills, right upper quadrant pain, and jaundice (Charcot trias); sometimes, lethargy, confusion, and shock are additionally present. In many cases, biliary obstruction plays a leading role in the pathogenesis and is sometimes complicated by abscess formation \[[@B7]\]. Frequent causes of biliary obstruction are choledocholithiasis, benign biliary stenosis, strictures after biliary interventions as well as after ischemic (SSC) or sterile inflammation (PSC), and stenosis caused by malignant tumors. An overview of common underlying causes for biliary obstruction and inflammation is given in table [1](#T1){ref-type="table"}\[[@B8]\]. Quite often, acute cholangitis and cholecystitis are due to biliary obstruction and ascending infection of the bile. In the vast majority of cases, bacteria are the causative infective organisms for acute biliary infections. In some populations, immunosuppressed viral (cytomegalovirus) or parasitic agents (cryptosporidia, isospora) \[[@B9]\] may be found. This article focuses on the majority of cases, which are due to bacterial infections.

The bacteria commonly found in biliary tract infections are well known. Most of these bacteria originate from the upper and lower intestine (table [2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}) \[[@B10],[@B11]\]. The bile of healthy subjects is generally aseptic. However, bile cultures are positive for microorganisms in 16% of the patients, in 72% of those with acute cholangitis, in 44% in chronic cholangitis patients, and in 50% of those with biliary obstruction \[[@B10],[@B11],[@B12]\].

Management {#sec1_3}
==========

Patients suspected of having acute cholangitis or cholecystitis should be admitted to a hospital for further evaluation. An early assessment of disease severity is essential for all of these patients (table [4](#T4){ref-type="table"}, [5](#T5){ref-type="table"}) \[[@B1]\].

Patient Assessment {#sec1_4}
==================

All patients with suspected or proven cholangitis or cholecystitis (table [6](#T6){ref-type="table"}) should be evaluated and grouped according to the TG13 severity assessment criteria (table [7](#T7){ref-type="table"}) \[[@B1],[@B2]\].

Early diagnosis, early biliary drainage or treatment for etiology, and antimicrobial administration are fundamental for the treatment for acute cholangitis/cholecystitis not only in severe and moderate but also in mild disease.

Therefore, it is recommended that patients with acute cholangitis/cholecystitis who do not respond to the initial medical treatment (general supportive care and antimicrobial therapy) undergo early biliary drainage or treatment for etiology, and, in the case of cholecystitis, surgical therapy.

Diagnostic Procedures {#sec1_5}
=====================

Identifying the causative organism is an essential step in the management of acute biliary infections.

Blood cultures are not routinely recommended for non-severe acute cholecystitis. The Surgical Infection Society and the Infectious Diseases Society of America (SIS-NA/IDSA) guidelines from 2010 advise against routine blood cultures for community-acquired intra-abdominal infections, since the results do not change the management and outcomes \[[@B13],[@B14]\]. Positive rates of blood cultures among patients with acute cholangitis ranged from 21 to 71% \[[@B15]\]. However, we would recommend taking cultures as it is simple, easy to take, and might mandate changes in therapy.

Bile cultures should be obtained at the beginning of any surgical or endoscopic procedure. Cultures of bile and tissue should be performed when perforation, emphysematous changes, or necrosis of gallbladder are noted during cholecystectomy. Positive rates of bile cultures range from 59 to 93% for acute cholangitis and from 29 to 67% for acute cholecystitis. Table [2](#T2){ref-type="table"} shows common microbial isolates from bile cultures among patients with acute biliary infections \[[@B11],[@B12],[@B13],[@B14],[@B15]\].

In patients with confirmed cholangitis or cholecystitis, management consists of three cornerstones: i) supportive care, ii) empiric antibiotic coverage, and iii) biliary drainage in acute cholangitis and final surgical treatment for acute cholecystitis.

Supportive care consists of fluid reconstitution, pain management, and management of complications \[[@B1],[@B14],[@B16]\]. For biliary drainage in acute cholangitis, endoscopic retrograde cholangiopancreatography (ERCP) is the treatment of choice. The optimal point of time depends on the severity of illness \[[@B17]\]. Early laparoscopic cholecystectomy is the standard definitive management for acute calculous cholecystitis \[[@B18]\].

Antimicrobial Therapy for Cholangitis and Cholecystitis {#sec1_6}
=======================================================

The rationale for antimicrobial therapy is to prevent both a systemic septic response and a local inflammation. Furthermore, it should prevent infections after surgical procedures as well as intrahepatic abscess formation. The selection of antibiotics is essential since inadequate initial antibiotic therapy is an independent predictor of mortality \[[@B19]\].

Before choosing an antimicrobial therapy several points should be considered: suspected pathogens, local epidemiology and resistance patterns, pharmacodynamics and pharmacokinetics, the history of antimicrobial usage, severity of illness, nosocomial or community-acquired nature of infection, and allergies or adverse reactions \[[@B1]\].

The antimicrobial therapy should be initiated as soon as the diagnosis of cholangitis or cholecystitis is suspected. While antibiotics should be administered immediately for patients with suspected septic shock, up to 4 h could be spent for obtaining definitive diagnosis in other patients. In all patients, antimicrobial therapy should be started before any invasive procedure \[[@B1],[@B2],[@B10],[@B17],[@B19],[@B20]\].

To this day, only few randomized controlled trials have evaluated the effect of antimicrobial therapy on acute cholangitis and/or cholecystitis \[[@B1]\]. All these studies, except one from 2012, are outdated and were conducted in part with antibiotics no longer used in clinical practice. Comparisons of these trials are quite complex as they differ in tested antibiotics, study design, and tested population. However, all of them demonstrated that the chosen antibiotics had a comparable effectiveness and usefulness with ampicillin and an aminoglycoside, which was considered to be the standard regime for acute cholecystitis in the 1980s \[[@B21]\]. The nowadays widely used penicillin and β-lactamase inhibitors, the carbapenems, and the third- and fourth-generation cephalosporins were mainly not tested in these randomized controlled trials. In spite of this, the TG for antimicrobial therapy for acute cholangitis and cholecystitis (TG13) updated in 2013 and the SIS/IDSA 2010 define recommendations for antimicrobial treatment depending on severity of illness and the community-acquired and healthcare-associated nature of biliary infections \[[@B1],[@B14]\]. Tables [6](#T6){ref-type="table"} and [7](#T7){ref-type="table"} summarize antimicrobial recommendations of TG13 and SIS/IDSA for acute community-acquired cholangitis.

Several antibiotic regimes based on different antimicrobial classes seem to be reasonable. For cholecystitis and cholangitis with mild-to-moderate severity, the TG13 guidelines include penicillin-, cephalosporin-, carbapenem-, monobactam-, and, with limitations, fluorchinolone-based therapy regimes. In contrast, the SIS/IDSA guidelines for mild-to-moderate cholangitis/cholecystitis recommend only cephalosporin-based regimes. The use of ampicillin/sulbactam as a monotherapy is no longer recommended because of high rates of resistance to this agent among community-acquired *Escherichia coli*\[[@B14]\]. In face of the increasing number of multidrug-resistant Gram-negative bacteria (MDRGN bacteria) and *Klebsiella* in the community, it should be noted that these organisms are not sufficiently covered by cephalosporins, penicillin derivatives, or fluorchinolones \[[@B21],[@B22]\]. If more than 10-20% of isolates in the community are resistant, empiric therapy should cover these resistant organisms until susceptibility data are available \[[@B14]\].

One randomized prospective trial from 2012 evaluated the effect of preoperative antibiotic treatment in 84 patients who underwent delayed cholecystectomy. In this study, there were no statistically significant differences regarding duration of hospitalization and rate of readmission between patients who received antibiotic treatment with amoxicillin/clavulanic acid until discharge and those who received no antibiotic treatment \[[@B23]\]. However, it should be noted that the chosen antibiotics are no longer recommended as monotherapy, and both the TG from 2013 and the guidelines by the SIS/IDSA still recommend the initiation of antimicrobial therapy when infection is suspected. The data of one recently published paper justify the use of broad-spectrum antimicrobial regimens for the empirical treatment of acute cholangitis in patients undergoing stent therapy to minimize the risk of a therapy failure before antimicrobial susceptibility testing is available \[[@B24]\].

For grade III cholangitis and cholecystitis, both guidelines recommend antimicrobial regimes with antipseudomonal activity for initial therapy as *Pseudomonas aeruginosa* could be detected in approximately 20% of the patients in recent studies \[[@B15],[@B22]\]. Additionally, *Enterococcus* sp. is an important pathogen in patients with grade III community-acquired cholangitis or cholecystitis. Therefore, vancomycin should be added in all cases of severe acute cholangitis or cholecystitis to cover *Enterococcus* sp. \[[@B1],[@B2],[@B3],[@B14]\].

For all patients with a biliary-enteric anastomosis, coverage of anaerobic pathogens is recommended irrespective of the severity of illness \[[@B1],[@B14]\].

Treatment of healthcare-associated biliary infection should be based on an empirical antimicrobial treatment that includes agents with antipseudomonal activity. The TG13 expand this recommendation to include empirical coverage against multidrug-resistant bacteria \[[@B1]\].

Once results of susceptibility testing become available, treatment should be narrowed.

So far, no well-designed and randomized controlled trials have evaluated the optimal treatment duration for community-acquired and healthcare-associated cholangitis or cholecystitis. One observational study from 2013 showed that antimicrobial therapy for more than 4 days after urgent cholecystectomy was not associated with fewer surgical site infections than antimicrobial treatment for up to 4 days \[[@B25]\]. In patients with mild cholecystitis, the TG13 recommend to stop antimicrobial therapy within 24 h after cholecystectomy is performed. In grade I-III cholangitis as well as in cholecystitis before definitive surgical therapy, the antimicrobial therapy should be continued for 4-7 days. If bacteremia with Gram-positive cocci such as *Enterococcus* sp. or *Streptococcus* spp. is present, a minimum duration of 2 weeks is recommended in some publications and guidelines, though the rationale remains unclear \[[@B1],[@B10],[@B25]\]. We believe that a shorter course of treatment is feasible when sufficient antibiotic bioavailability is granted and when the antibiotic is tailored according to pathogen susceptibility.

Patients who tolerate oral food intake may be treated with oral antimicrobial therapy \[[@B26]\]. The selection of oral antimicrobial agents should be guided by susceptibility patterns of the organisms identified \[[@B1],[@B7]\].

Summary and Recommendations {#sec1_7}
===========================

Current guidelines for the management of acute cholangitis and cholecystitis recommend the following procedures. Due to a lack of evidence from well-designed studies all current recommendations dealing with antimicrobial therapy are mainly based on expert opinion.

1.  Patients suspected of having acute cholangitis or cholecystitis should be admitted to a hospital. A clinical assessment should be performed for severity grading.

2.  Blood culture should be taken before initiating empiric antibiotic therapy and, whenever feasible, bile cultures should be taken.

3.  Empiric, antibiotic therapy tailored according to clinical and epidemiological findings must get initiated early (\<4 h).

4.  Adjunctive therapy (fluid management, pain management, antipyretics) should be administered.

5.  Drainage therapy must get offered early in the course of illness, preferably by means of ERCP. For cholecystitis, definitive surgical therapy must be evaluated from the beginning.

6.  In mild cholecystitis, antibiotic therapy may be stopped 24 h after surgery.

7.  Empirical antibiotics should be tailored after the results of susceptibility testing become available.

8.  Antimicrobial therapy should be given for 4-7 days.
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###### 

Etiology of acute cholangitis (modified according to \[[@B8]\])

  ------------------------------------------------------------------------------
  Cholelithiasis
  Benign biliary stricture
  After surgical, endoscopic, or other invasive procedures, ERCP complications
  Inflammatory factors (oriental cholangitis etc.)
  Sclerosing cholangitis
  Malignancies
  Bile duct tumor
  Gallbladder tumor
  Pancreatic tumor
  Duodenal tumor or diverticulum
  Pancreatitis
  Parasites in bile ducts
  External compression or adhesion
  Fibrotic papilla
  Obstruction by blood clot
  ------------------------------------------------------------------------------

###### 

Microorganisms isolated from bile cultures among patients with acute biliary infections (modified according to \[[@B10], [@B11]\])

  Organisms                  Proportion, %
  -------------------------- ---------------
   Gram-negative organisms   
   *Escherichia coli*        31--44
   *Klebsiella* spp.         9--20
   *Pseudomonas* spp.        0.5--19
   *Enterobacter* spp.       5-9
   *Acinetobacter* spp.      --
   *Citrobacter* spp.        --
  Gram-positive organisms    
   *Enterococcus* spp.       3-34
   *Streptococcus* spp.      2-10
   *Staphylococcus* spp.     --
   Anaerobes                 4--20

###### 

Commonisolates from patients with bacteremic biliary tract infections (modified according to \[[@B10], [@B11]\])

                           Proportion, % 35--62
  ------------------------ ----------------------
  Community-acquired       
   *Escherichia coli*      35--62
   *Klebsiella* spp.       12--28
   *Pseudomonas* spp.      4--14
   *Enterobacter* spp.     2--7
   *Acinetobacter* spp.    3
   *Citrobacter* spp.      2--6
  Healthcare-associated    
   *Enterococcus* spp.     10--23
   *Streptococcus* spp.    6--9
   *Staphylococcus* spp.   2
   Anaerobes               1
  Others                   17

###### 

Diagnostic criteria for acute cholangitis (TG13) (modified according to \[[@B12]\])[^a^](#T4F1){ref-type="table-fn"}

  -------------------------------------------------------------------------------------------
  A. Systemic inflammation
   Fever and/or chills
   Laboratory evidence of inflammation
  B. Cholestasis
   Jaundice
   Abnormal liver function tests
  C. Imaging
   Biliary dilatation
   Evidence of the etiology on imaging (obstruction, stricture, stone, stent, empyema etc.)
  -------------------------------------------------------------------------------------------

Suspected diagnosis: One item in A and one item in either B or C.

###### 

Severity assessment criteria for acute cholangitis/cholecystiti (TG13) (modified according to \[[@B12]\])

  ---------------------------------------------------------------------------------------------------------------------------------------------------------
  *Grade I*
  Grade I (mild) acute cholangitis/cholecystitis does not meet the criteria of Grade III (severe) or Grade II (moderate) acute cholangitis
  *Grade II*
  Grade II (moderate) acute cholangitis/cholecystitis at initial diagnosis is associated with any two of the following conditions:
   Abnormal WBC count (\>12,000/mm^3^, \<4,000/mm^3^)
   High fever (\>39.0 °C)
   Age (\>75 years)
   Hyperbilirubinemia (total bilirubin \>5 mg/dl)
  *Grade III*
  Grade III (severe) acute cholangitis/cholecystitis is associated with cardiac, renal, neurological, respiratory, hepatic, and hematological dysfunction
  ---------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Antimicrobial recommendations for acute biliary infections (TG13) (modified according to \[[@B1]\])

                         Cholangitis and cholecystitis, severity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  ---------------------- -------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Anti-microbial agent   ampicillin/sulbactam is not recommended without an aminoglycoside; cefazolin, cefotiam, cefuroxime, ceftriaxone, cefotaxim ± metronidazole   piperacillin/tacobactam; ceftriaxone, cefotaxim, cefepim, ceftacidim; ciprofloxacin, levofloxacin ± metronidazole, moxifloxacin ± metronidazole; impinem/ celastin, meropenem ± vancomycin, linezolid, daptomycin   piperacillin/tacobactam ± vancomycin, linezolid, daptomycin; ceftriaxone, cefotaxim, cefepim, ceftacidim, metronidazole ± vancomycin, linezolid, daptomycin; impinem/celastin, meropenem ± vancomycin, linezolid, daptomycin; impinem/celastin, meropenem ± vancomycin, linezolid, daptomycin   piperacillin/tacobactam ± vancomycin, linezolid, daptomycin; cefepim, ceftacidim ± metronidazole ± vancomycin, linezolid, daptomycin; imipenem/ cilastin, meropenem ± vancomycin, linezolid, daptomycin

###### 

Agents and regimens that may be used for the initial empiric treatment of biliary infection in adults (SIS/IDSA 2010) (modified according to \[[@B14]\])

  Infection                                                                                                            Regimen
  -------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Community-acquired acute cholecystitis of mild-to-moderate severity                                                  cefazolin, cefuroxime, or ceftriaxone
  Community-acquired acute cholecystitis of severe physiologic disturbance, advanced age, or immunocompromised state   imipenem-cilastatin, meropenem, doripenem, piperacillin-tazobactam, ciprofloxacin, levofloxacin, or cefepime, each in combination with metronidazole
  Acute cholangitis following bilio-enteric anastamosis of any severity                                                imipenem-cilastatin, meropenem, doripenem, piperacillin-tazobactam, ciprofloxacin, evofloxacin, or cefepime, each in combination with metronidazole
  Health care-associated biliary infection of any severity                                                             imipenem-cilastatin, meropenem, doripenem, piperacillin-tazobactam, ciprofloxacin, levofloxacin, or cefepime, each in combination with metronidazole, vancomycin added to each regimen
